All In Biotech

Drug Trial Radar · NCT05484414

Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

A Two-Part Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Ascending Oral Doses of SRP-3D (DA), and to Characterize the Effect of Food on the Pharmacokinetics of SRP-3D (DA), in Healthy Male and Female Subjects

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Dec 30, 2021

Primary completion

Nov 6, 2023

Study completion Nov 6, 2023

Sponsor

Lead sponsor
South Rampart Pharma, Inc.Industry
Sponsor type
Industry
First posted
Aug 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a two-part randomized, double-blind, placebo-controlled study.

Conditions

  • Pain

Interventions

  • SRP-3D (diethylamide)Drug

    SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL

  • PlaceboDrug

    Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: The time of providing written informed consent until 30 days after the last dose of study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences-Miami, Inc.

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.